IJBPAS, September, 2022, 11(9): 4292-4310

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

SOLID DISPERSION TECHNIQUES FOR POORLY WATER-SOLUBLE DRUGS – AN OVERVIEW

V. MANIKANDAN[*1], N. SRINIVASAN[1], S. DHANALAKSHMI[2] AND R. MURALI[1]

1: Department of Pharmacy, Annamalai University, Chidambaram, Tamilnadu, India

2: Department of Pharmacognosy, GRT Institute of Pharmaceutical Education and Research, Tiruttani, Tamilnadu, India

***Corresponding Author: V. Manikandan E Mail: saravanamani481@gmail.com**

Received 16th Oct. 2021; Revised 20th Nov. 2021; Accepted 20th Jan. 2022; Available online 1st Sept. 2022

https://doi.org/10.31032/IJBPAS/2022/11.9.6398

ABSTRACT

In terms of the administration of drugs, oral administration is the most prevalent and favoured mode of administration because of its simplicity and ease of consumption. The water solubility, drug permeability, dissolution rate, and first-pass metabolism of a medication all affect oral bioavailability. Novel chemical entities are created in pharmaceutical companies to account for more than 40% of poorly water-soluble drugs. Drugs with low water solubility may be improved by using the solid dispersion approach. Solvent-free solid dispersion may be made using this method. One or more of the methods listed in this study may be employed to improve the drug's solubility. The most critical consideration when choosing a solubility-enhancing approach is ensuring that the intended objectives are achieved. Dispersion of a solid method involves a variety of mechanisms. The dissolving of solids is carried out using a variety of methods and characterizations. Hence, this review will be used for new formulation of drugs to provide good solubility if the drugs have been low solubility in the upcoming drug developments.

Keywords: New drugs, poorly water solubility, solid dispersion, enhancement techniques

INTRODUCTION

Water-insoluble medicines remain a challenging but crucial class of pharmacological compounds for a range of disorders. For now, we don't know enough

about how the changes that occur between injection and absorption impact bioavailability both individually and collectively. We're continuously discovering them at a quick pace. The lack of water solubility causes a lot of treatments to fail in future stages of development, even after they pass high-throughput screening at the beginning of the selection process **[1]**. Most drugs that are just mildly water-soluble do not dissolve in adequate digestive juices. For these drugs, dissolution kinetics and limited bioavailability are critical. Water solubility may be improved via microspheres, phospholipids, macrocyclic contacts, nanocrystalline growth, co-crystal emergence, and saline generation. One possible technique for increasing drug bioavailability is solid dispersion (SD), which may induce and sustain supersaturation. An increase in intraluminal medication concentrations may be achieved by dispersing high-energy drugs fast under situations of supersaturation. Solid dispersion formulations, which turn the crystalline ingredient into an amorphous state, may increase the bioavailability of crystalline drugs. A solid dispersion containing one or more substances currently under examination in an insoluble matrix is created using a solvent evaporation technique and a melting operation. Disorganizing the crystal lattice structure of crystalline materials uses more energy than disorganizing the amorphous lattice structure or the crystal lattice structure. On the other hand, the thermodynamic instability and recrystallization potential of amorphous molecules, constitute a danger. Polymers in solid dispersions may help stabilise the medication's amorphous form and prevent re-crystallization. Two of these processes are the solid dispersion and dose form of anti-plasticizer polymers **[2-4]**. In SD, reducing the particle size enhances changes in porosity, wettability, and polymorphism. Solvent evaporation, melting, or solvent wetting may all be used to create a solid dispersion. Utilizing solid dispersion procedures, PVP K25 has been utilised to make water-soluble plant medications like quercetin. Researchers discovered that by using polyvinyl pyrrolidone as a spherical flocculation and dispersing agent of silymarin, they could boost the solubility and pharmacological characteristics of quercetin by solid dispersion. With the help of semicrystalline dissemination, nano-crystalline solid dispersion, and nano-emulsions, curcumin's physical and pharmacokinetic properties have been enhanced. According to the researchers, the pharmacokinetics of the formulations have significantly improved. For curcumin with

high photo-chemical stability, dissolution and pharmacokinetics may assist in boosting its bioavailability. This may be due to the transformation from crystalline to amorphous and the attachment of hydrophilic carriers on the surfaces of herbal drugs that aren't highly water soluble, which resulted in greater dissolving performance in trials utilising solid dispersions. These strategies may be used to generate a more stable solid dispersion. Multiple physical and chemical characteristics, carrier selection criteria, and explanations for solid dispersion instability are explored in this paper. To prevent medications from crystallising or precipitating, discuss and identify some additional current ways. This is the most convenient and simple technique for delivering the drug. There are several benefits to using the mouth to administer medication, such as better stability and dosing precision, as well as a smaller footprint. The oral route has long been considered the most common and preferred method of delivery because of its simplicity of administration and comfort. Convenient for patients, dosage forms may be taken by mouth. As high-throughput screening of potential therapeutics expands, so does the number of drug candidates with solubility issues. This is a major issue for pharmaceutical formulation experts. Oral administration of several active medications might cause significant problems with medication absorption, solubility and rate of dissolution **[5]**. In order to increase the oral bioavailability of active ingredients, pharmaceutical researchers are primarily focused on boosting the solubility of poorly water-soluble drugs and the permeability of weakly permeable pharmaceuticals. Class II drugs in the Biopharmaceutical Classification System have high membrane permeability but low water solubility (BCS). Class II BCS drugs may benefit greatly from the use of solid dispersion (SD) technologies since they improve absorption and bioavailability when taken orally.

Solid dispersion-based drug release mechanism

To allow for drug dispersion and erosive erosion, water entry into a tablet polymer matrix causes the matrix to expand. The formation of a gel layer aids in the stabilisation of the medication when it is oversaturated. Drug precipitation or recrystallization may occur after fast degradation of the polymer. The rate at which a medication diffuses over a gel layer is what determines the rate at which it dissolves in carrier-controlled dissolution. Precipitation and in-vivo solubility might

be altered by the presence of substances in the body such as fatty acids or bile salts **[6]**.

ELEMENTS OF SOLID DISPERSION

Eutectics in combination

Two chemicals are combined in a eutectic combination, which is only partly soluble in the solid state but completely soluble in the liquid state. Condensed eutectic that are totally miscible in water but not solid may be combined by rapidly cooling to produce a single solid.

Amorphous precipitation occurs in a crystallized matrix

Rather from forming a simple eutectic mixture, the medicine precipitates out as amorphous crystals.

Solid solution's

No matter how many components are in a solid solution, there is only one phase. Carrier dissolving rate determines how quickly the medication dissolves into the carrier's molecular dimensions. The miscibility (continuous vs discontinuous solid solutions) of a substance might influence its solubility or dispersion in the solvendum (substitutional, interstitial or amorphous) **[7-10]**.

Dissolving solids on a continuous basis

In a constant condition of continuous solid solution, any component may be completely dissolved. Because of this, the theoretical strength of the two components is greater than the strength of the molecules of each individual component. Until recently, the pharmaceutical industry has not reported on therapeutic therapies of this kind.

The solutions, as opposed to continuous solids

Because of this constraint, the solubility of discontinuous solid solutions is restricted. Only when the solubility of the two components is more than 5% can a "solid solution" be used.

Alternatives to well-supported arguments

Substitution is not possible until the solute and solvent molecules differ by more than 15% in size. Crystal lattices may accommodate either a replacement for the solvent molecules or interstices between the solvent molecules for solute molecules.

Solids in the solution's interstices

Molecularly dispersed compounds often fill up the spaces between neighboring molecules of their solvents in interstitial solid solutions. Only molecules with diameters less than 0.59 times the solvent's diameter should be used as solutes in chemical reactions **[10]**.

Glass and suspensions

The solute dissolves into the glass container in glass solutions. Precipitated particles are dissolved in a glass solvent and suspended in a solution in a glass suspension. The

lattice energies of glass solution and suspension are lower.

On the surface, dispersion

In order to make the surface solid dispersion more soluble, polymers such polyethylene glycol, polyvinyl pyrrolidone, and polyvinyl pyrrolidone-vinyl acetate copolymer are fused into it. Surface solid dispersion, a procedure that enables the medicine to be deposited on the surface of certain materials, may affect the dissolving capabilities of a medication. With an inert carrier, medication may be broken down at a faster pace since it is smaller in size **[11]**.

SOLID DISPERSION POLYMERS

An ethylene glycol-based composite (PEG)

It's called "polyethylene glycol" since it's made by combining ethylene glycol and ethylene oxide. It is common to refer to polyethylene oxides (PEGs) with a molecular weight of greater than 300,000 as PEGs.

Polypeptides

Other typical phospholipid head groups include choline, ethanolamine, serine, inositol and inositol, as well as glycerol esters and inositol phosphate. Head groups and fatty acid changes at the first and second positions on the glycerol backbone allow for a wide range of different species. Phospholipid solubility is directly tied to the integrity of the aggregate material, rather than a chemical function. Micelles containing monoacyl phospholipids may be dissolved more easily in aqueous solutions.

The molecular weight of PVP and effects

In the molecular weight range of 10,000 to 700,000, Polyvinyl Pyrrolidone (PVP) is a solid. Many solvents may be used for dissolving it, such as isopropyl alcohol, chloroform, ethanol, and methanol. Solid dispersions can't be made with PVP at higher temperatures because the polyvinylpyrrolidone decomposes. Compared to PEG, the molecular weight of PVP has a more consistent effect on pharmaceutical dissolving rates **[12]**. As PVP's molecular weight grows, the dissolving rate of most medicines will decrease. As the PVP solution's molecular weight grows, the likelihood of drug molecules dispersing into the dissolving solvent decreases. Prior to dissolving PVP, swelling of the polymer leads in an increase in both the polymer and drug dissolution rate.

Cyclodextrins

To boost solubility, prevent chemical reactions, or guard against chemical reactions or hide the product's flavor, cyclodextrins solidify liquids **[13-14]**.

STABILITY OF AMORPHOUS SOLID DISPERSION MAY BE IMPROVED BY USING SEVERAL TECHNIQUES IN CONJUNCTION WITH IT.

System for delivering drugs in a coamorphous form

As a substitute for macromolecules such as polymers, co-formers of low molecular weight have been used in recent years to stabilize the amorphous solid. A single phase amorphous solid system known as the Coamorphous system requires two or more components. Two kinds of coamorphous systems exist: drug-drug and drug-excipient. There were urea, sugar, carboxylic acid, and amino acids as excipients in coamorphous drug-excipient systems. Solubility and physical stability in the coamorphous system are improved by the use of certain amino acids as co-formers. It is possible to stabilize indomethacin in amorphous state and increase its solubility by up to 200 times by using arginine as a co-former **[15]**. More pharmaceuticals may be added to amorphous medications as long as two or more medications can successfully stabilize themselves in the amorphous state. This medicine may also be used in conjunction with other medications to provide a synergistic effect.

Solid dispersion that can be controlled by pH

Solid dispersions may be made to improve a medication's oral absorption and water solubility, however in certain situations, this can lead to drug recrystallization and precipitation. Chemicals such as pH-modifiers may be able to bypass this barrier and boost the water solubility of the medicine under these conditions **[16-18]**. To improve solubility, pH modifiers might be useful. Solubility may be increased by the interaction of the functional groups of pH modifiers with medicines.

A solid dispersion based on surfactants

Surfactants are used to dissolve and plasticize medicines and polymers, which also lowers the glass transition temperature by a substantial amount. With docusate sodium and tween-80 as surfactants, multiple polymer-carriers were plasticized using hot-melt extrusion to produce solid dispersions. Surfactant may be used in the formulation of medications to increase both dissolution and stability. If you're employing surfactants, you'll have to deal with issues like increased evaporation due to solid dispersion, the degradation of surfactant in the extruder, and a lower glass transition temperature **[17]**.

Solid dispersion with a long-term release

Short half-lived medications may be administered through solid dispersion, which reduces administration frequency. Concentration-dependent toxicities might need less frequent dosing of the medication. By restricting the rate of supersaturation, the drug's recrystallization is likewise avoided. Sustained-release

formulations that employ amorphous solid dispersions face a number of challenges, including drug recrystallization within the dosage form, problems with drug diffusion through the gelatinous layer, and difficulty obtaining the requisite supersaturation state **[17]**.

SOLID DISPERSION PREPARATION METHODS

Using a melting technique

The melting technique is the most often utilized method by pharmaceutical firms, however there are others, such as those proposed by Sekiguchi-Obi in the early 1990s. Following cooling, the mixture is agitated rapidly in an ice bath to solidify. Crushing, grinding, and sieving generate a fine powder from the final solid mass. These improvements include the pouring of homogeneous melt onto a stainless-steel surface and cooling it with flowing air/water on the other side of the plate. Supersaturation may occur in systems where rapid cooling of a melt from high temperature causes solutes or medications to overflow **[19]**. The solute molecule is held in place by the solidified solvent matrix at these circumstances. Simple eutectic mixtures may be finely dispersed using a quenching process.

Method that involves the use of solvents

A solvent-free film is left in its place when the drug and carrier are dissolved in a common solvent. To guarantee that the weight of the film is consistent, it is dried a second time. Soluble organic solvent evaporation prevents medication or carrier decomposition at low temperatures because of this **[20]**.

The method of melting solvents

An immaculate, solvent-free film is created by melting the medication and evaporating the polyethylene glycol melt. The "melting solvent procedure" is often referred to as this. To maintain the same weight, the film is re-dried. When combined with up to 10% (w/w) liquid material, polyethylene glycol6000 remains solid. The chosen solvent or dissolved medication may not be compatible with the polyethylene glycol melting temperature. The drug's polymorphic form, which precipitates as a solid dispersion, may also be affected by the liquid solvent. Using this method, the best aspects of solvent evaporation and fusion may be combined **[21-24]**. Only medications with a therapeutic dosage of less than 50 mg are appropriate from a practical viewpoint.

Melting and extrusion

Drug/carrier combination is commonly made using a twin-screw extruder. Tablets, granules, pellets, sheets, or powder may be extruded from the melted and homogenized drug/carrier combination. Conventional tablets may then be made from the

intermediates. Because the drug/carrier combination is heated for just a few seconds, drugs that are thermolabile may be processed using the hot melt extrusion technique. This is a significant benefit. High temperatures are used to mix the active ingredient and its carrier into an extruded solid dispersion. The dispersion's drug concentration is always set at 40% (w/w). One kilogram of material is put into the barrel per hour. The barrel includes two mixing zones and three transportation zones spread out along its length. There are five unique temperature zones on the railway. A conveyer belt takes the extrudates through the machine as soon as they cool to room temperature. To remove particles larger than 355 microns, samples are first crushed for one minute in a laboratory cutting mill **[23]**.

Techniques for lyophilization

A product's mass and heat must be transferred to and from it in order for freeze-drying to be successful. An alternative to solvent evaporation was given in the form of this method. When it comes to lyophilization, it's typically been thought of as combining the drug and carrier in a shared solvent, followed by freezing and subsequent sublime of the combination to create a molecular dispersion **[25]**.

Solids are melted and compacted during this process

The binder is utilized as a transporter to produce SD in this method. Using either the melt-in approach or the spray-on technique, a high-shear mixer38 may be used to disseminate the medication in the molten binder across the heated excipient. An alternative to melt agglomeration equipment, rotating processors have shown to be a viable option. Compared to high-melt agglomeration technologies, rotating processors offer various advantages, including the ability to regulate temperature more precisely and include more binder material into the agglomerates. SD(s) via melt agglomeration may be produced using a wide range of different binder types, production procedures, and particle sizes. The agglomeration dissolving process may be affected by all of these characteristics, including the rate at which agglomerates dissolve, their size and distribution, and their density. Because of the immersion mechanism of agglomeration formation and development, the melt-in process had a higher disintegration rate than the spray-on technique with PEG 3000 and poloxamer 188. Because of this, there is a more uniform dispersion of medications when they melt **[26]**. Agglomerates are completely adhered to when small particles are dispersed and consolidated, but when

large particles are present, densification takes place.

Using a surfactant may help

Surfactant systems are widely known in the process of solubilization. Material surface charge, hydrophobicity, and other important qualities influence interfacial processes such as flocculation/dispersion, floating, wetting, solubilization, and detergency. Adsorption of surfactant onto a solid surface may alter these properties. The melting point of active medicinal components, the glass transition temperature, and the combined glass transition temperature of solid dispersions all decrease when surfactants are used to improve solvation/plasticization. Some researchers are interested in the use of surfactants for dispersing solids.

Electrospinning

A millimeter-sized tip may be used to electro spin polymer solution or melt into solid fibers. A capillary is connected to a reservoir of polymer solution or melt and a conducting collecting screen in order to collect the polymer solution or melt. The hemispherical form of a pendant drop destabilizes into a conical shape as the electrostatic field intensity approaches but does not exceed a threshold point (commonly known as Taylor s cone). A polymer jet is fired from the cone's apex when a certain value is surpassed (as a way of relieving the charge built-up on the surface of the pendant drop). Whenever the charged jet is released, its electrostatic force pulls it toward the collecting screen. Due to the Coulombic repulsion force, the jet thins as it approaches the collecting screen **[27-29]**. It becomes more difficult to thin the charged jet as it dries because the viscosity increases. In the future, nanofibers and drug delivery can be controlled using this technology because of its low cost and simplicity.

Technology for fluids that are very important

It was originally presented in the late 1980s and early 1990s, and there are multiple experimental proofs of concept in the scientific literature for a broad variety of model compounds, such as medicines, polymers, explosives, superconductor precursors' dyes, and biomolecule precursors. Since the commencement of research into biomaterial polymers and drug-loaded bio composite microparticles, supercritical fluid microparticles for pharmaceutical purposes have been extensively investigated. Gas, SEDS, and/or particles from the gas-saturated solution may be used in conjunction with a fast expansion from a supercritical fluid and/or an antisolvent (PGSS). Drying items via spraying, solvent evaporation, or utilizing hot melts may result in reduced

yields or the loss of active components. Antisolvents are utilized in supercritical fluid antisolvent procedures, while solvents are used in organic solvent antisolvent techniques. Some of the acronyms used to characterize micro ionization processes were PCA precipitation, gas anti-solvent, solution increased diffusion by supercritical fluids, and supercritical anti-solvent (SAS). An organic solvent solution is sprayed into a supercritical fluid stream as part of SAS. Although a little quantity of supercritical carbon dioxide remains in the polymeric materials, it offers no hazard to patients since it can be promptly removed after the procedure. This may be done at temperatures as low as 39 degrees Celsius with the use of carbon dioxide **[30]**.

Using a spray drying method

After atomizing a solution and drying it into droplets, the process was repeated. Particles that are both spherical and finely distributed may be produced by this type of synthesis. Dissolving drug and carrier in volatile organic solvents is made easier by a magnetic stirrer. For liquids to be evaporated at 40^{o}C under low pressure, vacuum evaporators are used. A desiccator produces dry bulk in one to two days, depending on the amount of solvent that is removed from the product. To finish things off, the product is given a mesh size that is suitable. Using organic solvents, this method disperses and dissolves the medication and its carrier molecule. Drug and carrier combination drying in an anhydrous calcium chloride desiccator may take from one to two days, depending on the rate at which solvents are absorbed **[31]**. During the procedure, there are three basic steps: Sifting via a sieve with an adequate mesh size after crushing, pulverizing, and screening. Solid dispersions of Etoricoxib, Carbamazepine, and Glibenclamide were successfully synthesized using this method.

Method of dropping

Spherical particles have never before been created from dispersed elements using this procedure. Drug carrier mixture hardens into balls after being dropped onto a plate. Viscosity and pipette size have an impact on particle sizes and shapes. There are no issues with solvent evaporation since organic chemicals are not employed in the drop approach. Additionally, problems like pulverization, sieving, and compressibility may be avoided with this procedure **[32]**.

Method of FBD system

In a fluidized bed, the excipients or sugar spheres are granulated, and a drug carrier solution is sprayed over the excipients' granular surface. Both controlled and immediate-release solid dispersions have been created using this technology. To coat the sugar beads, Itraconazole and HPMC

(hydroxy propyl methylcellulose) are mixed in dichloromethane and ethanol. Closure of the Wurster technique allows drugs to be administered into the body by the controlled drying of coated beads. A high saturation concentration of Itraconazole is released when this thin film dissolves in water or saliva. The HPMC stabilizes and inhibits re-crystallization of Itraconazole. Itraconazole's supersaturated solutions are quite stable when it comes to absorbing and dispersing.

Kneading technique

Kneading wet drug and carrier mixtures in a glass mortar for 30 minutes produces the final product. After vacuum drying for 24 hours, it is sieved through 60 mesh and placed in a desiccator for storage. Mixtures of PVP and valdecoxib were made homogenous by knifing them together. There are certain drugs that are tough to dissolve that this procedure does not work with **[33]**.

Complexes of included information

Water-soluble polymers/drug-included cyclodextrin (CD) aggregates may be made with less cyclodextrin than nonaggregate CDs, which means they can be used in a broader range of drug delivery methods. For the most part, drug-CD complexes are created by either adding a significant quantity of drug to the CD and solvent slurry, kneading the mixture for a long period, and then drying and sifting the resultant paste. This approach cannot be used with all drugs that have a low water solubility.

Filling directly into the capsule

Capsule grinders do not alter the crystallinity of solid dispersions if the liquid melt is promptly packed into firm gelatin capsules. After cooling to ambient temperature, this liquid dispersion solidifies inside the capsule to prevent cross-contamination and operator exposure in a dust-free environment. This process is also more consistent in terms of fill weight and content than the classic powder-filling technique. Because Polyethylene glycol dissolved more quickly than this carrier, drug-rich layers would build on the surface of dissolving plugs, preventing the drug from dissolving any further. If a drug-rich layer is to be avoided, a surfactant must be included in the carrier.

Reduction in particle size

The smaller the drug particle, the less bioavailability the medication has. Smaller-surface-area particles dissolve more readily, enabling a wider range of formulations and delivery strategies.

Co-evaporates

Before evaporation of the solvent is employed to mix the two solutions, an organic solvent is dissolved in two separate solutions of the drug and copolymer. Co-

evaporates are often utilized in dermatological products. Examples are hydrocortisone - PVP and betamethasone dipropionate – PVP **[33]**.

Co-precipitate

Co-precipitation is a well-known method for increasing the bioavailability of water-soluble medications. Mixture is swirled continually as drops of nonsolvent are added one at a time to drug and carrier solution. During the nonsolvent addition procedure, medicine and carrier particles are generated. After the final micro particle suspension has been filtered and dried, it is ready to be used.

ANALYSIS OF SOLID DISPERSION CHARACTERISTICS

Crystallinity in a solid dispersion may be studied

The medicine may be found in a range of different molecular configurations in solid dispersions. Solid dispersions' molecular structure has been examined several times. There is more focus on amorphous and crystallized materials. An array of methods for determining the amount of crystalline material in a dispersion may be discovered. In order to determine the amount of amorphous material in the sample, only the amount of crystallinity may be employed in the sample **[34]**. It is beneficial to measure the quantity of amorphous drug crystallinity, but it does not reveal whether the amorphous drug particles or molecularly dispersed molecules are present in the sample.

To identify a material's crystalline phase

It is possible to detect materials with long-range order by using powder X-ray diffraction. Diffraction peaks provide further crystallographic details. This has happened in the last several years with the development of semiquantitative X-ray equipment. Drug-matrix interactions may be studied using infrared spectroscopy (IR). Vibrational patterns that are specific to crystallinity may be used to detect their presence. For pure materials, Fourier Transformed Infrared Spectroscopy allowed for crystallinity values of up to 99.999% to be correctly determined (FTIR). There was no way to identify solid dispersions quantitatively **[35]**. To utilize water vapor sorption to distinguish between crystallinity and amorphous materials, we require reliable data on the hydrophobicity of both. Isothermal In order to estimate the crystallization energy of an amorphous material, microcalorimetry is performed (Tg). However, there are certain drawbacks to this method. This technique can only be used if crystallization occurs just during the measurement and the stability is sufficient. Always, amorphous materials crystallize. The crystallization energies of the drug and the matrix are difficult to distinguish in a

binary combination of two amorphous substances. Dissolution Calorimetry considers crystallinity when determining the energy required to dissolve a sample. It is more frequent for crystals to dissolve than for amorphous materials to dissolve exothermically. The degree of crystallinity may be assessed using macroscopic methods that distinguish between the mechanical characteristics of amorphous and crystalline materials. Density measurements and Dynamic Mechanical Analysis (DMA) are used to determine crystallinity-related modulus of elasticity and viscosity, respectively (DMA). DMA. Additionally, understanding the interactions between these features in binary solids is required for the execution of certain procedures. DSC is the most widely used method for determining crystallinity (DSC). Increasing the temperature requires a greater quantity of energy, which is measured in DSC. Thermal events may be detected with the use of a DSC. Re-crystallization, melting, or deterioration may occur as a result of thermal processes. The melting and (re)crystallization energy may also be quantified. It is possible to measure the quantity of crystallized material by using melting energy. The amount of amorphous material delivered may be estimated by the reconciliation of the substance. When amorphous materials crystallize, the crystallization kinetics and physical stability may be determined **[36-38]**. The quantity of crystallized material should be determined prior to crystallization. In certain circumstances, high-speed scanning may be able to do this.

An amorphous solid dispersion's molecular structure may be studied using this method

Regular distribution of medication has a significant impact on the features of solid dispersion. Depending on the kind of solid dispersion, type II or type III solid dispersions might be more stable or more dissolvable. Regardless of whether the medicine is crystalline or amorphous, understanding how it disperses in a solid dispersion is critical (amorphous or crystalline particles or individual drug molecules). There hasn't been much study on the differences between amorphous incorporation particles and molecular dispersion or homogeneity. This study employed Confocal Raman Spectroscopy to assess the homogeneity of PVP containing ibuprofen. A medication's content is said to be uniformly distributed if the standard deviation is less than ten percent. It's impossible to see nano-sized amorphous drug particles, which are 2 μm 3 pixels in size.IR or FTIR may be used to measure how much a drug interacts with its matrix. As opposed to when they are grouped in

amorphous clusters or other multi-molecule structures, the drug molecules that are distributed have more interactions with the matrix. TMDSC has the authority to make a determination on the inclusion of a medication (Temperature Modulated Differential Scanning Calorimetry). Modulation allows us to tell the difference between activities that are reversible and those that are not. Reversible glass transitions are distinguished from irreversible crystallization or relaxation in amorphous materials, for example. To elaborate, the Tg value may be affected by the makeup of the combination **[39]**. According to study, TMDSC is more sensitive than normal DSC. This method may be used to estimate the amount of medicine that has been molecularly disseminated, which is a measure of how many individual molecules there are.

SUCCESSIVE POTENTIALS

Despite its numerous benefits, solid dispersion has not been widely used in commercial dosage forms for medications that are poorly water-soluble because to the problems in manufacturing, repeatability, formulation, scaling-up and stability. These days, preclinical and clinical solid dispersion systems may be created using carriers that are surface-active and self-emulsifying yet nevertheless have low melting temperatures. In order to make dosage forms, pharmaceuticals are dissolved in melting carriers and heated solutions are placed in gelatin capsules. As the product is mass-produced and scaled up, its physical and chemical qualities are likely to alter dramatically. We expect an increase in solid dispersion systems' use with water-soluble drugs very soon **[40]**. In the early stages of drug research, the dosage form may be made and created with modest concentrations of medicinal components, however micronization is a conventional strategy for increasing bioavailability.

CONCLUSION

In order for a weakly water-soluble medication to be absorbed from the gastrointestinal system through the oral route, the drug must first be dissolvable in water. One or more of the methods listed above may be employed to improve the drug's solubility. The most critical consideration when choosing a solubility-enhancing approach is ensuring that the intended objectives are achieved. Drug characteristics, such as solubility and melting point, absorption site, physical nature and pharmacokinetic behavior, as well as dosage form requirements like tablet or capsule formulation, strength and so forth, and regulatory requirements such as maximum daily dose of any excipients and drug, approved excipients, analytical

accuracy dictate the solubility enhancement method. Hence, this review will be used for new formulation of drugs to provide good solubility if the drugs have been low solubility in the upcoming drug developments.

CONFLICT OF INTEREST

The authors have no conflicts of interest regarding this investigation.

REFERENCES

[1] Boyd, B. J., Bergström, C., Vinarov, Z., Kuentz, M., Brouwers, J., Augustijns, P., Brandl, M., Bernkop-Schnürch, A., Shrestha, N., Préat, V., Müllertz, A., Bauer-Brandl, A., & Jannin, V. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. European journal of pharmaceutical sciences, 2019; 1(137), 104967.

[2] Brouwers, J., Brewster, M. E., & Augustijns, P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability. Journal of pharmaceutical sciences, 2009; 98(8), 2549–2572.

[3] Chavan, R. B., Rathi, S., Jyothi, V., & Shastri, N. R. Cellulose based polymers in development of amorphous solid dispersions. Asian journal of pharmaceutical sciences, 2019; 14(3), 248–264.

[4] Janssens, S., & Van den Mooter, G. Review: physical chemistry of solid dispersions. The Journal of pharmacy and pharmacology, 2009; 61(12), 1571–1586.

[5] Thenmozhi, K., & Yoo, Y. J. Enhanced solubility of piperine using hydrophilic carrier-based potent solid dispersion systems. Drug development and industrial pharmacy, 2017; 43(9), 1501–1509.

[6] Kokate, C.K., Purohit, A.P., Gokhale, S.B., Pharmacognosy, Nirali Prakashan, 50th edition, 2014; 15.70-15.71.

[7] Konno, H., Handa, T., Alonzo, D. E., & Taylor, L. S. (2008). Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. European journal of pharmaceutics and biopharmaceutics, 2008; 70(2), 493–499.

[8] Kubin, A., Loew, H. G., Burner, U., Jessner, G., Kolbabek, H., & Wierrani, F. (2008). How to make hypericin water-soluble. Die Pharmazie, 2008; 63(4), 263–269.

[9] Lindfors, L., Forssén, S., Westergren, J., & Olsson, U.

Nucleation and crystal growth in supersaturated solutions of a model drug. Journal of colloid and interface science, 2008; 325(2), 404–413.

[10] Maincent, J., & Williams, R. O. Sustained-release amorphous solid dispersions. Drug delivery and translational research, 2018; 8(6), 1714–1725.

[11] Marsac, P. J., Shamblin, S. L., & Taylor, L. S. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharmaceutical research, 2006; 23(10), 2417–2426.

[12] Meere, M., McGint, S., Pontrelli, G. Mathematically modelling the dissolution of solid dispersions. In: Proceedings of the Equadiff2017 Conference, 2018; 341–348.

[13] Ucisik, M. H., Küpcü, S., Schuster, B., & Sleytr, U. B. (2013). Characterization of CurcuEmulsomes: nano formulation for enhanced solubility and delivery of curcumin. Journal of nanobiotechnology, 2013; 6(11), 37.

[14] Mukherjee, P.K. Bioactive phytocomponents and their analysis: Quality Control and Evaluation of Herbal Drugs, 2018; 237–328.

[15] Nair, A. R., Lakshman, Y. D., Anand, V., Sree, K., Bhat, K., & Dengale, S. J. Overview of Extensively Employed Polymeric Carriers in Solid Dispersion Technology. AAPS PharmSciTech, 2020; 21(8), 309.

[16] Onoue, S., Takahashi, H., Kawabata, Y., Seto, Y., Hatanaka, J., Timmermann, B., & Yamada, S. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. Journal of pharmaceutical sciences, 2010; 99(4), 1871–1881.

[17] Schittny, A., Huwyler, J., & Puchkov, M. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug delivery, 2020; 27(1), 110–127.

[18] Shakeel, F., Haq, N., Siddiqui, N.A., Alanazi, F.K., Alsarra, I.A. Thermody- namics of the solubility of reserpine in {{2-(2 ethoxyethoxy) ethanol + water}} mixed solvent systems at different temperatures. The Journal of

Chemical Thermodynamics, 2015; 85, 57-60.

[19] Su, S., Wu, J., Gao, Y., Luo, Y., Yang, D., & Wang, P. The pharmacological properties of chrysophanol, the recent advances. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020; 125, 110002.

[20] Sun, Y., Zhu, L., Wu, T., Cai, T., Gunn, E. M., & Yu, L. Stability of amorphous pharmaceutical solids: crystal growth mechanisms and effect of polymer additives. The AAPS journal, 2012; 14(3), 380–388.

[21] Taniguchi, C., Kawabata, Y., Wada, K., Yamada, S., & Onoue, S. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility. Expert opinion on drug delivery, 2014; 11(4), 505–516.

[22] Tiwari, A., Mahadik, K.R., Gabhe, S.Y. Piperine: a comprehensive review of methods of isolation, purification, and biological properties. Medicine in drug discovery, 2020; 7, 2590-2599.

[23] Tran, T. T., Tran, P. H., Choi, H. G., Han, H. K., & Lee, B. J. The roles of acidifiers in solid dispersions and physical mixtures. International journal of pharmaceutics, 2010; 384(1-2), 60–66.

[24] Vranic E. Amorphous pharmaceutical solids. Bosnian journal of basic medical sciences, 2014; 4(3), 35–39.

[25] Wang, J., Qian, Y., Qian, C., Shi, F., Yao, J., Bi, X., & Chen, Z. A novel β-cyclodextrin-rhein conjugate for improving the water solubility and bioavailability of rhein. Carbohydrate research, 2020; 4(490), 107958.

[26] Yildiz, G., Aydo ğmu ş , Z., Senkal, F., et al. Investigation of Curcumin water solubility through emulsifying with biocompatible polyethylene glycol–based polymers. Food analytical methods, 2019; 12, 2129-2138.

[27] Arunachalam A, Karthikeyan M, Konam K, Prasad P, Sethuraman S, Ashutoshraman S. Solid dispersions: a review. Journal of Drug Delivery and Therapeutics, 2010; 2(4), 82-90.

[28] Patel PB, Prajapati ST, Patel NR, Patel NN, Patel CN. Solid

dispersion: a method of improving bioavailability and taste masking. Pharmacy and Technology, 2013; 3, 427-39.

[29] Ranade VV, Canon JB. Drug delivery systems. 3rd edition, 2011; 231-234.

[30] OG Bhusnure, PA Kazi, SB Gholve, MMAW Ansari, SN Kazi. Review article solid dispersion: an evergreen method for solubility enhancement of poorly water-soluble drugs. International journal of research in pharmaceutical chemistry, 2014; 4, 906-918.

[31] Zhang, X., Xing, H., Zhao, Y., & Ma, Z. Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs. Pharmaceutics, 2013; 10(3), 74.

[32] Paudwal, G., Rawat, N., Gupta, R., Baldi, A., Singh, G., & Gupta, P. Recent Advances in Solid Dispersion Technology for Efficient Delivery of Poorly Water-Soluble Drugs. Current pharmaceutical design, 2019; 25(13), 1524–1535.

[33] Kaushik, R., Budhwar, V., & Kaushik, D. An Overview on Recent Patents and Technologies on Solid Dispersion. Recent patents on drug delivery & formulation, 2020; 14(1), 63–74.

[34] Bikiaris D. N. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert opinion on drug delivery, 2011; 8(11), 1501–1519.

[35] Chivate, A., Garkal, A., Dhas, N., & Mehta, T. Hot-Melt Extrusion: An Emerging Technique for Solubility Enhancement of Poorly Water-Soluble Drugs. PDA journal of pharmaceutical science and technology, 2021; 75(4), 357–373.

[36] Abuzar, S. M., Hyun, S. M., Kim, J. H., Park, H. J., Kim, M. S., Park, J. S., & Hwang, S. J. Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process. International journal of pharmaceutics, 2018; 538(1-2), 1–13.

[37] Gala, U. H., Miller, D. A., & Williams, R. O. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochimica et

biophysica acta. Reviews on cancer, 2020; 1873(1), 188319.

[38] Shah, S., Maddineni, S., Lu, J., & Repka, M. A. Melt extrusion with poorly soluble drugs. International journal of pharmaceutics, 2013; 453(1), 233–252.

[39] Kumar, S., & Gupta, S. K. Pharmaceutical solid dispersion technology: a strategy to improve dissolution of poorly water-soluble drugs. Recent patents on drug delivery & formulation, 2013; 7(2), 111–121.

[40] Alam, M. A., Ali, R., Al-Jenoobi, F. I., & Al-Mohizea, A. M. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates. Expert opinion on drug delivery, 2012; 9(11), 1419–1440.